Robert Clark
Directeur/Bestuurslid bij INCANNEX HEALTHCARE INC.
Vermogen: 230 000 $ op 30-04-2024
Profiel
Robert Bruce Clark currently works at Incannex Healthcare, Inc., as Independent Non-Executive Director from 2022 and Novo Nordisk, Inc., as Vice President-Regulatory Affairs from 2012.
Mr. Clark also formerly worked at Pfizer Inc., as Head-United States Regulatory Strategy from 1992 to 2021.
Mr. Clark received his graduate degree from New York Medical College.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
INCANNEX HEALTHCARE INC.
0.63% | 21-12-2023 | 100 000 ( 0.63% ) | 230 000 $ | 30-04-2024 |
Actieve functies van Robert Clark
| Bedrijven | Functie | Begin |
|---|---|---|
| INCANNEX HEALTHCARE INC. | Directeur/Bestuurslid | 17-08-2022 |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Algemeen Adviseur | 01-01-2012 |
Eerdere bekende functies van Robert Clark
| Bedrijven | Functie | Einde |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01-01-2021 |
Opleiding van Robert Clark
| New York Medical College | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| INCANNEX HEALTHCARE INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |